title: Interleukin-13 receptor alpha 2-targeted glioblastoma immunotherapy.
abstract: Glioblastoma (GBM) is the most lethal primary brain tumor, and despite several refinements in its multimodal management, generally has very poor prognosis. Targeted immunotherapy is an emerging field of research that shows great promise in the treatment of GBM. One of the most extensively studied targets is the interleukin-13 receptor alpha chain variant 2 (IL13Rα2). Its selective expression on GBM, discovered almost two decades ago, has been a target for therapy ever since. Immunotherapeutic strategies have been developed targeting IL13Rα2, including monoclonal antibodies as well as cell-based strategies such as IL13Rα2-pulsed dendritic cells and IL13Rα2-targeted chimeric antigen receptor-expressing T cells. Advanced therapeutic development has led to the completion of several clinical trials with promising outcomes. In this review, we will discuss the recent advances in the IL13Rα2-targeted immunotherapy and evaluate the most promising strategy for targeted GBM immunotherapy.
authors.affiliation: Roger Williams Medical Center Brain Tumor Laboratory, 825 Chalkstone Avenue, Prior 222, Providence, RI 02908, USA ; Department of Neurosurgery, Boston University School of Medicine, Boston, MA 02118, USA.
authors.forename: Sadhak
authors.identifier: 0000-0002-5933-4430
authors.initials: S
authors.lastname: Sengupta
authors.affiliation: Department of Neurosurgery, Boston University School of Medicine, Boston, MA 02118, USA.
authors.forename: Bart
authors.identifier: 0000-0001-5392-7174
authors.initials: B
authors.lastname: Thaci
authors.affiliation: University of Illinois College of Medicine, Urbana-Champaign, IL 61801, USA.
authors.forename: Andrew C
authors.initials: AC
authors.lastname: Crawford
authors.affiliation: Roger Williams Medical Center Brain Tumor Laboratory, 825 Chalkstone Avenue, Prior 222, Providence, RI 02908, USA ; Department of Neurosurgery, Boston University School of Medicine, Boston, MA 02118, USA.
authors.forename: Prakash
authors.identifier: 0000-0001-5994-6819
authors.initials: P
authors.lastname: Sampath
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000276:immunology*; D019317:Evidence-Based Medicine; D005909:Glioblastoma / Q000188:drug therapy* / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D053663:Interleukin-13 Receptor alpha2 Subunit / Q000037:antagonists & inhibitors / Q000276:immunology*; D058990:Molecular Targeted Therapy / Q000379:methods; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D053663:Interleukin-13 Receptor alpha2 Subunit